Amgen Fights Regeneron's Cancer Patent Challenge
Amgen Pharmaceuticals is denying all claims that its patents protecting molecules used in cancer treatment are invalid, fighting a bid from rival Regeneron to nix the patents as the pharma giants'...To view the full article, register now.
Already a subscriber? Click here to view full article